GlassScriptPhysician profile
Anne-Marie Addleton
NPI 1912623646
$6,876.17
in general payments reported to CMS, 2019-2025
35 companies · $2,451 in 2025
The $2,451 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,176 · 2024: $2,248 · 2025: $2,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,876.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $931.08 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $883.88 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $590.62 | 2023-2025 | |
| Amgen INC. | $588.31 | 2023-2025 | Tepezza, Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $483.89 | 2023-2025 | |
| Corcept Therapeutics | $435.08 | 2023-2025 | Korlym |
| Tandem Diabetes Care, INC. | $348.13 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $280.14 | 2023-2025 | Minimed 780g |
| Dexcom, INC. | $268.37 | 2023-2025 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $237.30 | 2023-2025 | Tirosint, Tirosint, Licart |
| Xeris Pharmaceuticals, INC. | $202.46 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.62 | 2023-2025 | Jardiance |
| Beta Bionics, INC. | $167.96 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Antares Pharma, INC. | $148.39 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Insulet Corporation | $147.73 | 2023-2024 | Omnipod |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $116.78 | 2023 | |
| Ascendis Pharma Endocrinology INC | $116.58 | 2025 | Yorvipath |
| Madrigal Pharmaceuticals | $87.20 | 2025 | Rezdiffra |
| Mannkind Corporation | $76.14 | 2023 | Afrezza |
| Sequel Med Tech, LLC | $61.47 | 2025 | Twiist |
| Ultragenyx Pharmaceutical INC. | $58.58 | 2023 | |
| Abbvie INC. | $53.56 | 2023 | Synthroid |
| Ascensia Diabetes Care US INC. | $45.76 | 2023 | |
| Radius Health, INC. | $43.27 | 2024 | |
| Cequr Corporation | $42.66 | 2023-2024 | Cequr Simplicity |
| Horizon Therapeutics Plc | $40.82 | 2023 | Tepezza |
| Glaxosmithkline, LLC. | $39.26 | 2025 | Arexvy, Shingrix |
| Abbott Laboratories | $35.80 | 2025 | |
| Kyowa Kirin, INC. | $27.23 | 2024 | Crysvita |
| Astrazeneca Pharmaceuticals LP | $26.64 | 2023 | Farxiga |
| Amneal Pharmaceuticals LLC | $26.60 | 2024 | Unithroid |
| Sanofi US Services INC. | $25.53 | 2024 | |
| Merck Sharp & Dohme LLC | $24.96 | 2025 | Welireg |
| Roche Diabetes Care, INC. | $24.01 | 2023 | Accu-Chek Guide Me |
| Azurity Pharmaceuticals, INC. | $18.36 | 2023 | Adthyza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne-Marie Addleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.